OVID
NASDAQ · Biotechnology
Ovid Therapeutics Inc
$2.43
+0.03 (+1.25%)
Financial Highlights (FY 2026)
Revenue
18.03M
Net Income
-43,268,015
Gross Margin
—
Profit Margin
-240.1%
Rev Growth
+69.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 35.9% | 35.9% |
| Operating Margin | -585.2% | -526.7% | -33.9% | -31.3% |
| Profit Margin | -240.1% | -228.1% | -26.8% | -31.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 18.03M | 10.66M | 31.11M | 33.06M |
| Gross Profit | — | — | 11.16M | 11.86M |
| Operating Income | -105,483,973 | -56,144,997 | -10,543,713 | -10,340,763 |
| Net Income | -43,268,015 | -23,029,873 | -8,350,078 | -10,285,734 |
| Gross Margin | — | — | 35.9% | 35.9% |
| Operating Margin | -585.2% | -526.7% | -33.9% | -31.3% |
| Profit Margin | -240.1% | -228.1% | -26.8% | -31.1% |
| Rev Growth | +69.1% | +69.1% | +19.5% | +23.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 32.20M | 24.28M |
| Total Equity | — | — | 114.62M | 121.51M |
| D/E Ratio | — | — | 0.28 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -42,590,235 | -23,928,513 | -13,566,183 | -16,328,398 |
| Free Cash Flow | — | — | -8,976,737 | -6,780,942 |